BISPECIFIC ANTIBODY
Provided are a novel antibody usable as an antitumor agent and an antitumor agent that comprises a molecule containing the antibody, etc. as an active ingredient. An antibody that contains heavy chain CDRH1 comprising the amino acid sequence represented by SEQ ID NO: 54, heavy chain CDRH2 comprising...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | HIROSHI SHIKU AYAKA YATSU RYUJI HASHIMOTO SHINJI FURUZONO YASUSHI AKAHORI SHIHO KOZUMA MAKIKO NAKAYAMA JUNYA ICHIKAWA ICHIRO WATANABE TOSHIAKI OHTSUKA KENTO TANAKA KENSUKE NAKAMURA NAOYA SHINOZAKI |
| description | Provided are a novel antibody usable as an antitumor agent and an antitumor agent that comprises a molecule containing the antibody, etc. as an active ingredient. An antibody that contains heavy chain CDRH1 comprising the amino acid sequence represented by SEQ ID NO: 54, heavy chain CDRH2 comprising the amino acid sequence represented by SEQ ID NO: 55, heavy chain CDRH3 comprising the amino acid sequence represented by SEQ ID NO: 56, light chain CDRL1 comprising the amino acid sequence represented by SEQ ID NO: 57 or light chain CDRL1 comprising an amino acid sequence that is identical with the amino acid sequence represented by SEQ ID NO: 57 except that the seventh amino acid is W and/or the eighth amino acid is K, light chain CDRL2 comprising the amino acid sequence represented by SEQ ID NO: 58, and light chain CDRL3 comprising the amino acid sequence represented by SEQ ID NO: 59 or light chain CDRL3 comprising an amino acid sequence that is identical with the amino acid sequence represented by SEQ ID NO: 57 except that the second amino acid is A or S; or a binding fragment of the antibody. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_ZA202211246B</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ZA202211246B</sourcerecordid><originalsourceid>FETCH-epo_espacenet_ZA202211246B3</originalsourceid><addsrcrecordid>eNrjZBB28gwOcHX2dPN0VnD0C_F08neJ5GFgTUvMKU7lhdLcDIpuriHOHrqpBfnxqcUFicmpeakl8VGORgZGRoaGRiZmTsbEqAEAVgseQw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>BISPECIFIC ANTIBODY</title><source>esp@cenet</source><creator>HIROSHI SHIKU ; AYAKA YATSU ; RYUJI HASHIMOTO ; SHINJI FURUZONO ; YASUSHI AKAHORI ; SHIHO KOZUMA ; MAKIKO NAKAYAMA ; JUNYA ICHIKAWA ; ICHIRO WATANABE ; TOSHIAKI OHTSUKA ; KENTO TANAKA ; KENSUKE NAKAMURA ; NAOYA SHINOZAKI</creator><creatorcontrib>HIROSHI SHIKU ; AYAKA YATSU ; RYUJI HASHIMOTO ; SHINJI FURUZONO ; YASUSHI AKAHORI ; SHIHO KOZUMA ; MAKIKO NAKAYAMA ; JUNYA ICHIKAWA ; ICHIRO WATANABE ; TOSHIAKI OHTSUKA ; KENTO TANAKA ; KENSUKE NAKAMURA ; NAOYA SHINOZAKI</creatorcontrib><description>Provided are a novel antibody usable as an antitumor agent and an antitumor agent that comprises a molecule containing the antibody, etc. as an active ingredient. An antibody that contains heavy chain CDRH1 comprising the amino acid sequence represented by SEQ ID NO: 54, heavy chain CDRH2 comprising the amino acid sequence represented by SEQ ID NO: 55, heavy chain CDRH3 comprising the amino acid sequence represented by SEQ ID NO: 56, light chain CDRL1 comprising the amino acid sequence represented by SEQ ID NO: 57 or light chain CDRL1 comprising an amino acid sequence that is identical with the amino acid sequence represented by SEQ ID NO: 57 except that the seventh amino acid is W and/or the eighth amino acid is K, light chain CDRL2 comprising the amino acid sequence represented by SEQ ID NO: 58, and light chain CDRL3 comprising the amino acid sequence represented by SEQ ID NO: 59 or light chain CDRL3 comprising an amino acid sequence that is identical with the amino acid sequence represented by SEQ ID NO: 57 except that the second amino acid is A or S; or a binding fragment of the antibody.</description><language>eng</language><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240228&DB=EPODOC&CC=ZA&NR=202211246B$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76293</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240228&DB=EPODOC&CC=ZA&NR=202211246B$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>HIROSHI SHIKU</creatorcontrib><creatorcontrib>AYAKA YATSU</creatorcontrib><creatorcontrib>RYUJI HASHIMOTO</creatorcontrib><creatorcontrib>SHINJI FURUZONO</creatorcontrib><creatorcontrib>YASUSHI AKAHORI</creatorcontrib><creatorcontrib>SHIHO KOZUMA</creatorcontrib><creatorcontrib>MAKIKO NAKAYAMA</creatorcontrib><creatorcontrib>JUNYA ICHIKAWA</creatorcontrib><creatorcontrib>ICHIRO WATANABE</creatorcontrib><creatorcontrib>TOSHIAKI OHTSUKA</creatorcontrib><creatorcontrib>KENTO TANAKA</creatorcontrib><creatorcontrib>KENSUKE NAKAMURA</creatorcontrib><creatorcontrib>NAOYA SHINOZAKI</creatorcontrib><title>BISPECIFIC ANTIBODY</title><description>Provided are a novel antibody usable as an antitumor agent and an antitumor agent that comprises a molecule containing the antibody, etc. as an active ingredient. An antibody that contains heavy chain CDRH1 comprising the amino acid sequence represented by SEQ ID NO: 54, heavy chain CDRH2 comprising the amino acid sequence represented by SEQ ID NO: 55, heavy chain CDRH3 comprising the amino acid sequence represented by SEQ ID NO: 56, light chain CDRL1 comprising the amino acid sequence represented by SEQ ID NO: 57 or light chain CDRL1 comprising an amino acid sequence that is identical with the amino acid sequence represented by SEQ ID NO: 57 except that the seventh amino acid is W and/or the eighth amino acid is K, light chain CDRL2 comprising the amino acid sequence represented by SEQ ID NO: 58, and light chain CDRL3 comprising the amino acid sequence represented by SEQ ID NO: 59 or light chain CDRL3 comprising an amino acid sequence that is identical with the amino acid sequence represented by SEQ ID NO: 57 except that the second amino acid is A or S; or a binding fragment of the antibody.</description><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZBB28gwOcHX2dPN0VnD0C_F08neJ5GFgTUvMKU7lhdLcDIpuriHOHrqpBfnxqcUFicmpeakl8VGORgZGRoaGRiZmTsbEqAEAVgseQw</recordid><startdate>20240228</startdate><enddate>20240228</enddate><creator>HIROSHI SHIKU</creator><creator>AYAKA YATSU</creator><creator>RYUJI HASHIMOTO</creator><creator>SHINJI FURUZONO</creator><creator>YASUSHI AKAHORI</creator><creator>SHIHO KOZUMA</creator><creator>MAKIKO NAKAYAMA</creator><creator>JUNYA ICHIKAWA</creator><creator>ICHIRO WATANABE</creator><creator>TOSHIAKI OHTSUKA</creator><creator>KENTO TANAKA</creator><creator>KENSUKE NAKAMURA</creator><creator>NAOYA SHINOZAKI</creator><scope>EVB</scope></search><sort><creationdate>20240228</creationdate><title>BISPECIFIC ANTIBODY</title><author>HIROSHI SHIKU ; AYAKA YATSU ; RYUJI HASHIMOTO ; SHINJI FURUZONO ; YASUSHI AKAHORI ; SHIHO KOZUMA ; MAKIKO NAKAYAMA ; JUNYA ICHIKAWA ; ICHIRO WATANABE ; TOSHIAKI OHTSUKA ; KENTO TANAKA ; KENSUKE NAKAMURA ; NAOYA SHINOZAKI</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_ZA202211246B3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>online_resources</toplevel><creatorcontrib>HIROSHI SHIKU</creatorcontrib><creatorcontrib>AYAKA YATSU</creatorcontrib><creatorcontrib>RYUJI HASHIMOTO</creatorcontrib><creatorcontrib>SHINJI FURUZONO</creatorcontrib><creatorcontrib>YASUSHI AKAHORI</creatorcontrib><creatorcontrib>SHIHO KOZUMA</creatorcontrib><creatorcontrib>MAKIKO NAKAYAMA</creatorcontrib><creatorcontrib>JUNYA ICHIKAWA</creatorcontrib><creatorcontrib>ICHIRO WATANABE</creatorcontrib><creatorcontrib>TOSHIAKI OHTSUKA</creatorcontrib><creatorcontrib>KENTO TANAKA</creatorcontrib><creatorcontrib>KENSUKE NAKAMURA</creatorcontrib><creatorcontrib>NAOYA SHINOZAKI</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>HIROSHI SHIKU</au><au>AYAKA YATSU</au><au>RYUJI HASHIMOTO</au><au>SHINJI FURUZONO</au><au>YASUSHI AKAHORI</au><au>SHIHO KOZUMA</au><au>MAKIKO NAKAYAMA</au><au>JUNYA ICHIKAWA</au><au>ICHIRO WATANABE</au><au>TOSHIAKI OHTSUKA</au><au>KENTO TANAKA</au><au>KENSUKE NAKAMURA</au><au>NAOYA SHINOZAKI</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>BISPECIFIC ANTIBODY</title><date>2024-02-28</date><risdate>2024</risdate><abstract>Provided are a novel antibody usable as an antitumor agent and an antitumor agent that comprises a molecule containing the antibody, etc. as an active ingredient. An antibody that contains heavy chain CDRH1 comprising the amino acid sequence represented by SEQ ID NO: 54, heavy chain CDRH2 comprising the amino acid sequence represented by SEQ ID NO: 55, heavy chain CDRH3 comprising the amino acid sequence represented by SEQ ID NO: 56, light chain CDRL1 comprising the amino acid sequence represented by SEQ ID NO: 57 or light chain CDRL1 comprising an amino acid sequence that is identical with the amino acid sequence represented by SEQ ID NO: 57 except that the seventh amino acid is W and/or the eighth amino acid is K, light chain CDRL2 comprising the amino acid sequence represented by SEQ ID NO: 58, and light chain CDRL3 comprising the amino acid sequence represented by SEQ ID NO: 59 or light chain CDRL3 comprising an amino acid sequence that is identical with the amino acid sequence represented by SEQ ID NO: 57 except that the second amino acid is A or S; or a binding fragment of the antibody.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_ZA202211246B |
| source | esp@cenet |
| title | BISPECIFIC ANTIBODY |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T09%3A39%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=HIROSHI%20SHIKU&rft.date=2024-02-28&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EZA202211246B%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |